A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)
Study of Durvalumab with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAT2261
U.S. Govt. ID: NCT04385368
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is aimed at finding patients who have small amounts of cancer DNA in their blood (called circulating tumor DNA or ctDNA) after surgery. This may indicate that you have minimal residual disease (MRD), meaning that even after surgery, there are still some remaining cancer cells releasing cancer DNA into your bloodstream. MRD after surgery may mean that the risk of cancer coming back is higher, which is why we would like to give additional treatment after your tumor has been removed. The study is focusing on subjects with stage II-III non-small cell lung cancer (NSCLC) that is being treated/has already been treated by removing it through surgery. This study will also investigate the safety of this new drug combination. Some patients will get durvalumab and chemotherapy and other patients will get a placebo and chemotherapy to see which prevents their lung cancer from coming back better.
This study is closed
Catherine Shu, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Have you been diagnosed with Non-Small Cell Lung cancer (NSCLC) (stage II-III)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator